ABSTRACT
Objetivo: Analizar el efecto del secukinumab sobre las variables propias reportadas por el paciente diagnosticado de artritis psoriásica y/o espondilitis anquilosante en relación con su estado de salud, dolor, fatiga, sueño y calidad de vida. Métodos: Se realizó un estudio observacional, longitudinal, prospectivo y multicéntrico a 6meses con 39 pacientes que iniciaron tratamiento con secukinumab para la terapia de artritis psoriásica y/o espondilitis. Las variables principales fueron los cambios en las medidas reportadas por el paciente, evaluándolas por medio de los cuestionarios FACIT-fatiga, Índice de Gravedad del Insomnio, EuroQol-3L-5D y PsAQoL. Adicionalmente, y dependiendo del tipo de enfermedad (psoriásica periférica o espondiloartritis), se recogió el DAS28 con velocidad o el BASDAI, respectivamente. Resultados: Los niveles de fatiga, insomnio moderado y grave presentan una reducción significativa tras el tratamiento de 6meses con secukinumab. Al mismo tiempo, la calidad de vida reportada por el paciente aumenta notablemente (p=0,006). Los datos referentes al dolor y a la incomodidad también presentan una notable mejoría tras el tratamiento. Conclusiones: Los pacientes de artritis psoriásica y/o espondilitis anquilosante que inician tratamiento con secukinumab presentan mejoría a los 6meses en todos los tamaños del efecto del tratamiento, particularmente en el sueño, la fatiga y la calidad de vida. Además, las medidas de desenlace reportadas por los pacientes son un valor clínico adicional y permiten realizar una valoración más exacta y aproximada de su estado real de salud y bienestar.(AU)
Objective: To analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life. Methods: A six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively. Results: Levels of fatigue, moderate and severe insomnia significantly reduced after 6months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P=.006). Data on pain and discomfort also show significant improvement after the treatment. Conclusions: Patients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being.(AU)
Subject(s)
Humans , Male , Female , Antibodies, Monoclonal, Humanized , Arthritis, Psoriatic/diagnosis , Arthritis, Psoriatic/drug therapy , Severity of Illness Index , Quality of Life , Fatigue , Sleep , Spondylitis , Prospective Studies , Longitudinal Studies , RheumatologyABSTRACT
OBJECTIVE: To analyse the effect of secukinumab on self-reported variables of patients diagnosed with psoriatic arthritis and/or ankylosing spondylitis in relation to their health status, pain, fatigue, sleep and quality of life. METHODS: A six-month, observational, longitudinal, prospective, multicentre study was conducted with 39 patients who initiated treatment with secukinumab as therapy for psoriatic arthritis and/or spondylitis. The main variables were changes in patient-reported measures and they were evaluated by means of the questionnaires: FACIT-fatigue, Insomnia Severity Index, EuroQol-3L-5D and PsAQoL. In addition, depending on the type of disease (peripheral psoriasis or spondyloarthritis) the DAS28 with ESR or the BASDAI were calculated, respectively. RESULTS: Levels of fatigue, moderate and severe insomnia significantly reduced after 6months of treatment with secukinumab. At the same time, patient-reported quality of life increased significantly (P=.006). Data on pain and discomfort also show significant improvement after the treatment. CONCLUSIONS: Patients with psoriatic arthritis and/or ankylosing spondylitis who start treatment with secukinumab show improvement at 6months in all effect sizes of the treatment, particularly in sleep, fatigue and quality of life. Furthermore, patient-reported outcome measures are of additional clinical value and allow more accurate and closer assessment of their real status of health and well-being.
ABSTRACT
La enfermedad de Behçet (EB) es una vasculitis sistémica, y afecta con mayor agresividad a varones jóvenes. Sus manifestaciones más frecuentes son las aftas orogenitales, la uveítis y las lesiones cutáneas. Analizamos 6 pacientes con EB, que recibieron adalimumab para controlar la enfermedad. Todos habían recibido terapia inmunosupresora, además 2 de ellos recibieron infliximab. Observamos una buena respuesta clínica al fármaco. Actualmente, con un seguimiento medio de 26,8 meses, los pacientes siguen en tratamiento con adalimumab, con buen control clínico y sin que se hayan detectado efectos adversos relacionados con el anti-TNF (AU)
Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab (AU)
Subject(s)
Humans , Male , Female , Adult , Behcet Syndrome/diagnosis , Behcet Syndrome/drug therapy , Uveitis/complications , Uveitis/diagnosis , Tumor Necrosis Factor-alpha/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Immunosuppressive Agents/therapeutic use , Uveitis/drug therapy , Cyclophosphamide/therapeutic use , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/pharmacologyABSTRACT
Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab.
